Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study

被引：23

作者：

Cowan, Annie ^{[1
]}

Ferrari, Federico ^{[1
,3
]}

Freeman, Samuel S. ^{[2
]}

Redd, Robert ^{[1
]}

El-Khoury, Habib ^{[1
]}

Perry, Jacqueline ^{[1
]}

Patel, Vidhi ^{[1
]}

Kaur, Priya ^{[1
]}

Barr, Hadley ^{[1
]}

Lee, David J. ^{[1
,4
]}

Lightbody, Elizabeth ^{[1
]}

Downey, Katelyn ^{[1
]}

Argyelan, David ^{[1
]}

Theodorakakou, Foteini ^{[5
]}

Fotiou, Despina ^{[5
]}

Liacos, Christine Ivy ^{[5
]}

Kanellias, Nikolaos ^{[5
]}

Chavda, Selina J. ^{[6
]}

Ainley, Louise ^{[6
]}

Sandecka, Viera ^{[7
]}

Pospisilova, Lenka ^{[8
]}

Minarik, Jiri ^{[9
]}

Jungova, Alexandra ^{[10
]}

Radocha, Jakub ^{[11
]}

Spicka, Ivan ^{[12
]}

Nadeem, Omar ^{[1
]}

Yong, Kwee ^{[6
]}

Hajek, Roman ^{[13
]}

Kastritis, Efstathios ^{[5
]}

Marinac, Catherine R. ^{[1
]}

Dimopoulos, Meletios A. ^{[5
]}

Get, Gad ^{[2
]}

Trippa, Lorenzo ^{[1
]}

Ghobrial, Irene M. ^{[1
,14
]}

机构：

[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[2] Broad Inst MIT & Harvard, Bioinformat Program, Cambridge, MA USA

[3] Merck & Co Inc, Biostat & Res Decis Sci, Rahway, NJ USA

[4] Massachusetts Gen Hosp, Dept Med, Boston, MA USA

[5] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece

[6] UCL, UCL Canc Inst, London, England

[7] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[8] Inst Biostat & Anal, Brno, Czech Republic

[9] Univ Hosp Olomouc, Dept Hematooncol, Olomouc, Czech Republic

[10] Univ Hosp Plzen, Dept Hematol & Oncol, Plzen, Czech Republic

[11] Charles Univ Prague, Univ Hosp Hradec Kralove, Fac Med Hradec Kralove, Dept Internal Med Hematol 4, Prague, Czech Republic

[12] Charles Univ Prague, Gen Hosp Prague, Fac Med 1, Dept Med 1, Prague, Czech Republic

[13] Univ Hosp Ostrava, Dept Internal Med Hematol 4, Ostrava, Czech Republic

[14] Dana Farber Canc Inst, Med Oncol, Boston, MA 02215 USA

来源：

LANCET HAEMATOLOGY | 2023年 / 10卷 / 03期

关键词：

MULTIPARAMETER FLOW-CYTOMETRY; RISK STRATIFICATION; ABNORMALITIES; DIAGNOSIS; CRITERIA; MGUS;

D O I：

10.1016/S2352-3026(22)00386-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Patients with precursors to multiple myeloma are dichotomised as having monoclonal gammopathy of undetermined significance or smouldering multiple myeloma on the basis of monoclonal protein concentrations or bone marrow plasma cell percentage. Current risk stratifications use laboratory measurements at diagnosis and do not incorporate time-varying biomarkers. Our goal was to develop a monoclonal gammopathy of undetermined significance and smouldering multiple myeloma stratification algorithm that utilised accessible, time-varying biomarkers to model risk of progression to multiple myeloma.Methods In this retrospective, multicohort study, we included patients who were 18 years or older with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma. We evaluated several modelling approaches for predicting disease progression to multiple myeloma using a training cohort (with patients at Dana-Farber Cancer Institute, Boston, MA, USA; annotated from Nov, 13, 2019, to April, 13, 2022). We created the PANGEA models, which used data on biomarkers (monoclonal protein concentration, free light chain ratio, age, creatinine concentration, and bone marrow plasma cell percentage) and haemoglobin trajectories from medical records to predict progression from precursor disease to multiple myeloma. The models were validated in two independent validation cohorts from National and Kapodistrian University of Athens (Athens, Greece; from Jan 26, 2020, to Feb 7, 2022; validation cohort 1), University College London (London, UK; from June 9, 2020, to April 10, 2022; validation cohort 1), and Registry of Monoclonal Gammopathies (Czech Republic, Czech Republic; Jan 5, 2004, to March 10, 2022; validation cohort 2). We compared the PANGEA models (with bone marrow [BM] data and without bone marrow [no BM] data) to current criteria (International Myeloma Working Group [IMWG] monoclonal gammopathy of undetermined significance and 20/2/20 smouldering multiple myeloma risk criteria).Findings We included 6441 patients, 4931 (77%) with monoclonal gammopathy of undetermined significance and 1510 (23%) with smouldering multiple myeloma. 3430 (53%) of 6441 participants were female. The PANGEA model (BM) improved prediction of progression from smouldering multiple myeloma to multiple myeloma compared with the 20/2/20 model, with a C-statistic increase from 0middot533 (0middot480-0middot709) to 0middot756 (0middot629-0middot785) at patient visit 1 to the clinic, 0middot613 (0middot504-0middot704) to 0middot720 (0middot592-0middot775) at visit 2, and 0middot637 (0middot386-0middot841) to 0middot756 (0middot547-0middot830) at visit three in validation cohort 1. The PANGEA model (no BM) improved prediction of smouldering multiple myeloma progression to multiple myeloma compared with the 20/2/20 model with a C-statistic increase from 0middot534 (0middot501-0middot672) to 0middot692 (0middot614-0middot736) at visit 1, 0middot573 (0middot518-0middot647) to 0middot693 (0middot605-0middot734) at visit 2, and 0middot560 (0middot497-0middot645) to 0middot692 (0middot570-0middot708) at visit 3 in validation cohort 1. The PANGEA models improved prediction of monoclonal gammopathy of undetermined significance progression to multiple myeloma compared with the IMWG rolling model at visit 1 in validation cohort 2, with C-statistics increases from 0middot640 (0middot518-0middot718) to 0middot729 (0middot643-0middot941) for the PANGEA model (BM) and 0middot670 (0middot523-0middot729) to 0middot879 (0middot586-0middot938) for the PANGEA model (no BM). Interpretation Use of the PANGEA models in clinical practice will allow patients with precursor disease to receive more accurate measures of their risk of progression to multiple myeloma, thus prompting for more appropriate treatment strategies.Copyright (c) 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

引用

页码：E203 / E212

页数：10

共 26 条

[1] Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma [J].

Atrash, Shebli ;

Robinson, Myra ;

Slaughter, Daniel ;

Aneralla, Amanda ;

Brown, Taylor ;

Robinson, Jordan ;

Ndiaye, Ami ;

Sprouse, Chelsea ;

Zhang, Qing ;

Symanowski, James T. ;

Friend, Reed ;

Voorhees, Peter M. ;

Usmani, Saad Z. ;

Bhutani, Manisha .

BLOOD CANCER JOURNAL, 2018, 8

[2] A NEW PROGNOSTIC SYSTEM FOR MULTIPLE-MYELOMA BASED ON EASILY AVAILABLE PARAMETERS [J].

BLADE, J ;

ROZMAN, C ;

CERVANTES, F ;

REVERTER, JC ;

MONTSERRAT, E .

BRITISH JOURNAL OF HAEMATOLOGY, 1989, 72 (04) :507-511

[3] Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression [J].

Bustoros, Mark ;

Sklavenitis-Pistofidis, Romanos ;

Park, Jihye ;

Redd, Robert ;

Zhitomirsky, Benny ;

Dunford, Andrew J. ;

Salem, Karma ;

Tai, Yu-Tzu ;

Anand, Shankara ;

Mouhieddine, Tarek H. ;

Chavda, Selina J. ;

Boehner, Cody ;

Elagina, Liudmila ;

Neuse, Carl Jannes ;

Cha, Justin ;

Rahmat, Mahshid ;

Taylor-Weiner, Amaro ;

Van Allen, Eliezer ;

Kumar, Shaji ;

Kastritis, Efstathis ;

Leshchiner, Ignaty ;

Morgan, Elizabeth A. ;

Laubach, Jacob ;

Casneuf, Tineke ;

Richardson, Paul ;

Munshi, Nikhil C. ;

Anderson, Kenneth C. ;

Trippa, Lorenzo ;

Aguet, Francois ;

Stewart, Chip ;

Dimopoulos, Meletios-Athanasios ;

Yong, Kwee ;

Bergsagel, P. Leif ;

Manier, Salomon ;

Getz, Gad ;

Ghobrial, Irene M. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (21) :2380-+

[4] Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group [J].

Bustoros, Mark ;

Kastritis, Efstathios ;

Sklavenitis-Pistofidis, Romanos ;

Liu, Chia-Jen ;

Hornburg, Kalvis ;

Kanellias, Nikolaos ;

Kim, Geon ;

Liu, David ;

Gavriatopoulou, Maria ;

Marinac, Catherine R. ;

Roussou, Maria ;

Migkou, Magdalini ;

Noonan, Kimberly ;

Reyes, Kaitlen ;

Rivotto, Bradley ;

Neuse, Carl Jannes ;

Ziogas, Dimitrios C. ;

Laubach, Jacob ;

Terpos, Evangelos ;

Anderson, Kenneth C. ;

Richardson, Paul G. ;

Ghobrial, Irene M. ;

Dimopoulos, Meletios A. .

AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (05) :E146-E149

[5] Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120) [J].

Dhodapkar, Madhav V. ;

Sexton, Rachael ;

Waheed, Sarah ;

Usmani, Saad ;

Papanikolaou, Xenofon ;

Nair, Bijay ;

Petty, Nathan ;

Shaughnessy, John D., Jr. ;

Hoering, Antje ;

Crowley, John ;

Orlowski, Robert Z. ;

Barlogie, Bart .

BLOOD, 2014, 123 (01) :78-85

[6] How I manage monoclonal gammopathy of undetermined significance [J].

Go, Ronald S. ;

Rajkumar, S. Vincent .

BLOOD, 2018, 131 (02) :163-173

[7]

Joseph Nisha S, 2020, Am Soc Clin Oncol Educ Book, V40, P1, DOI 10.1200/EDBK_278915

[8] Long-Term Biological Variation of Serum Protein Electrophoresis M-Spike, Urine M-Spike, and Monoclonal Serum Free Light Chain Quantification: Implications for Monitoring Monoclonal Gammopathies [J].

Katzmann, Jerry A. ;

Snyder, Melissa R. ;

Rajkumar, S. Vincent ;

Kyle, Robert A. ;

Therneau, Terry M. ;

Benson, Joanne T. ;

Dispenzieri, Angela .

CLINICAL CHEMISTRY, 2011, 57 (12) :1687-1692

[9] Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management [J].

Kyle, R. A. ;

Durie, B. G. M. ;

Rajkumar, S. V. ;

Landgren, O. ;

Blade, J. ;

Merlini, G. ;

Kroeger, N. ;

Einsele, H. ;

Vesole, D. H. ;

Dimopoulos, M. ;

San Miguel, J. ;

Avet-Loiseau, H. ;

Hajek, R. ;

Chen, W. M. ;

Anderson, K. C. ;

Ludwig, H. ;

Sonneveld, P. ;

Pavlovsky, S. ;

Palumbo, A. ;

Richardson, P. G. ;

Barlogie, B. ;

Greipp, P. ;

Vescio, R. ;

Turesson, I. ;

Westin, J. ;

Boccadoro, M. .

LEUKEMIA, 2010, 24 (06) :1121-1127

[10] Prevalence of monoclonal gammopathy of undetermined significance [J].

Kyle, RA ;

Therneau, TM ;

Rajkumar, SV ;

Larson, DR ;

Plevak, MF ;

Offord, JR ;

Dispenzieri, A ;

Katzmann, JA ;

Melton, LJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (13) :1362-1369

← 1 2 3 →